Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:26 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1247
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1045–1056 of 1,247 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 4 Interventional

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting No phase listed Observational

Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study

NCT07301216
Status at this site: Recruiting
View directory record Official record
Conditions
Wilson Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting No phase listed Observational

Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

NCT04237701
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure NYHA Class IV
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40,000 participants
Timeline
2019 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
idecabtagene vicleucel, Lenalidomide, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

NCT04416984
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting Not applicable Interventional

Optimizing Tracheal Intubation Outcomes and Neonatal Safety

NCT05838690
Status at this site: Recruiting
View directory record Official record
Conditions
Infant, Intubation Complication
Interventions
Personalized Intubation Safety (PINS) Bundle
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Little Rock, Arkansas • Denver, Colorado • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268
Site status not listed — check the official record
View directory record Official record
Conditions
NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Interventions
Oral MRT-2359
Drug
Lead sponsor
Monte Rosa Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06994806
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
KQB168, Pembrolizumab
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting No phase listed Observational

Time to BBVNA Relief

NCT07433634
Status at this site: Recruiting
View directory record Official record
Conditions
Low Back Pain, Vertebrogenic Pain Syndrome, Basivertebral Nerve Ablation
Interventions
Basivertebral nerve ablation
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Guilford, Connecticut • New Haven, Connecticut • Old Saybrook, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 1 Interventional

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

NCT06715124
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
QTX3544, Cetuximab
Drug · Combination Product
Lead sponsor
Quanta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Denver, Colorado • New Haven, Connecticut • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Active, not recruiting Phase 1 Interventional

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

NCT05907304
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Naporafenib, Trametinib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 2, 2026, 5:26 AM EST
Recruiting No phase listed Observational

Transformative Research in Diabetic Nephropathy

NCT02986984
Status at this site: Recruiting
View directory record Official record
Conditions
Diabetic Nephropathies, Diabetic Glomerulosclerosis
Interventions
There is no intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 2, 2026, 5:26 AM EST

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.